A systematic review and meta-analysis of higher expression of Folate receptor alpha (FOLR1) predicts poor cancer prognosis.

A systematic review and meta-analysis of higher expression of Folate receptor alpha (FOLR1) predicts poor cancer prognosis. Biomarkers. 2020 May 18;:1-20 Authors: Liu Y, Lian T, Yao Y Abstract Folate Receptor Alpha (FOLR1), a glycosylphosphatidylinositol-linked protein, is well characterized folate transporters. However, the prognostic power of FOLR1 in cancer remains controversial. We conducted a meta-analysis to assess the prognostic roles of FOLR1 on different cancers. 12 studies involving 4,471 patients were included in this meta-analysis. The pooled analysis indicated that high FOLR1 significantly predicted poor overall survival (OS) [pooled hazard ratio (HR) =0.78, 95% confidence interval (CI) =0.64-0.94, P = 0.009] and the disease-free survival (DFS) (HR =1.25, 95% CI =1.07-1.47, P = 0.005). Subgroup analyses based on tumor type found that high FOLR1 level was associated with poor OS in breast cancer (HR =2.66, 95% CI =1.54-4.59, P = 0.0005) and endometrial carcinoma (HR =1.30, 95% CI =1.05-1.61, P = 0.02). However, FOLR1 has relatively weakly correlation with gender, tumor size and chemotherapy. Additionally, overexpression of FOLR1 was correlated with grade, FIGO stage, vital status and nodule status. The present meta-analysis indicated that the high expression of FOLR1 is associated with the poor survival of cancer patients, which is helpful for the clinical decision-making process. PMID: 32421366 [P...
Source: Biomarkers - Category: Research Tags: Biomarkers Source Type: research